JAGX Jaguar Health Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Jaguar Health, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Jaguar Health, Inc. (NASDAQ: JAGX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

http://www.zlkdocs.com/JAGX-Info-Request-Form-6521

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
13/03/2018

Underlying

JAGXJaguar Health Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Jaguar Health Inc

 PRESS RELEASE
Free
JAGX Jaguar Health I...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Jaguar Health, Inc. (NASDAQ: JAGX) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/JAGX-Info-Request-Form-6521 or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. Levi & Korsinsky is a national firm with offices in New York, ...

March 13, 2018 1 EN
 PRESS RELEASE
Free
JAGX Jaguar Health I...

Jaguar Health Provides Updates Regarding Commercial, Educational & Pro...

SAN FRANCISCO--(BUSINESS WIRE)-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, today provided the following updates regarding commercial, educational and product development programs and 2017 results. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006522/en/ (...

January 22, 2018 1 EN
 PRESS RELEASE
Free
JAGX Jaguar Health I...

Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m...

SAN FRANCISCO--(BUSINESS WIRE)-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced today that Company management will host a conference call on Monday, January 22, 2018 at 4:15 p.m. Eastern Time to provide updates regarding Jaguar and Napo Pharmaceuticals commercial, educational and product development activities and 201...

January 18, 2018 1 EN
 PRESS RELEASE
Free
JAGX Jaguar Health I...

Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and ...

SAN FRANCISCO--(BUSINESS WIRE)-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ: JAGX), is deeply saddened by the passing of Dr. Mathilde Krim, Cofounder and Chairperson of the American Foundation for AIDS Research (amfAR). Dr. Krim was a pioneer in HIV research and her contributions have helped save countless lives and pave the way forwa...

January 18, 2018 1 EN
 PRESS RELEASE
Free
JAGX Jaguar Health I...

Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement ...

SAN FRANCISCO--(BUSINESS WIRE)-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced today that it has entered into a collaboration agreement (the Agreement) with Seed Mena Businessmen Services LLC (SEED) for Equilevia™, Jaguar’s non-prescription, personalized, premium product for total gut health in equine athletes. Based in Dubai in...

December 14, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch